Clementia is a privately held clinical-stage biopharmaceutical company focused on bringing effective new treatments to people who have none.
Our team has a proven track record of developing and commercializing orphan drugs. We are rapidly developing our lead product candidate, palovarotene, an investigational therapy for the treatment of fibrodysplasia ossificans progressiva (FOP) and other diseases.
Since its inception, Clementia has completed $92.5 million in financing to support the development of palovarotene for the treatment of FOP. Investors include New Enterprise Associates (NEA) and OrbiMed Partners, Inc. with participation by BDC Venture Group, UCB, RA Capital Management, Rock Springs Capital Management, EcoR1 Capital, and a fund advised by Janus Capital Management.
For further information, please contact: email@example.com